Genetic Predictors of Adverse Radiotherapy Effects (Gene-PARE)

A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity.

G. Barnett, Deborah Thompson, L. Fachal, et al.. (2014). Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. Cited 152 times. https://doi.org/10.1016/j.radonc.2014.02.012

Radiogenomics: using genetics to identify cancer patients at risk for development of adverse effects following radiotherapy.

S. Kerns, H. Ostrer, B. Rosenstein. (2014). Cancer discovery. Cited 106 times. https://doi.org/10.1158/2159-8290.CD-13-0197

A 2-stage genome-wide association study to identify single nucleotide polymorphisms associated with development of erectile dysfunction following radiation therapy for prostate cancer.

S. Kerns, R. Stock, N. Stone, et al.. (2013). International journal of radiation oncology, biology, physics. Cited 67 times. https://doi.org/10.1016/j.ijrobp.2012.08.003

A 2-stage genome-wide association study to identify single nucleotide polymorphisms associated with development of urinary symptoms after radiotherapy for prostate cancer.

S. Kerns, N. Stone, R. Stock, et al.. (2013). The Journal of urology. Cited 58 times. https://doi.org/10.1016/j.juro.2013.01.096

Genome-wide association study identifies a region on chromosome 11q14.3 associated with late rectal bleeding following radiation therapy for prostate cancer.

S. Kerns, R. Stock, N. Stone, et al.. (2013). Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. Cited 51 times. https://doi.org/10.1016/j.radonc.2013.05.001